High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 2, 2012, Pages 122-127

  Khraishi, Majed ^a,b,c,d   Chouela, Edgardo ^a,b,c,d   Bejar, Michelle ^a,b,c,d   Landells, Ian ^a,b,c,d   Hewhook, Trevor ^a,b,c,d   Rampakakis, Emmanouil ^a,b,c,d   Sampalis, John S ^a,b,c,d   Abouchehade, Kassem ^a,b,c,d  

^a Nexus Clinical Research Inc   (Canada)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c JSS Medical Research   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLASSIFICATION CRITERIA FOR PSORIATIC ARTHRITIS; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DERMATOLOGY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX SCORE; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS SCREENING QUESTIONNAIRE; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOLOGY; SCORING SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; SYNOVITIS;

ADULT; AGED; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEWFOUNDLAND AND LABRADOR; PREVALENCE; QUESTIONNAIRES;

EID: 84860321482     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.10101     Document Type: Article

References (24)

1. Peters JP, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92, doi:10.1016/j.semarthrit.2004.07.010. (Pubitemid 39643120)
2. Gladman DD, Anhorn KAB, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92. (Pubitemid 16058075)
3. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome [review]. Ann Rheum Dis 2005;64 Suppl 2:ii14-7, doi:10.1136/ard.2004.032482. (Pubitemid 40288513)
4. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriasis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-9, doi:10.1002/art.24172.
5. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in patients with psoriasis. Arthritis Care Res 2009;61:1373-8, doi:10.1002/art.24608.
6. Gladman DD. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994;8:379-94, doi:10.1016/S0950-3579(94)80024-3. (Pubitemid 24189845)
7. Gisondi P, Girolomoni G, Sampogna F, et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005;15:279-83. (Pubitemid 41020858)
8. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7, doi:10.2165/00128071- 200304070-00001. (Pubitemid 36871763)
9. Brockbank JE, Schentag C, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees [abstract]. Arthritis Rheum 2001;44 Suppl 9:S94.
10. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573, doi:10.1016/j.jaad.2005.03.046.
11. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007;57:581-7, doi:10.1016/j.jaad.2007.04.001. (Pubitemid 47384917)
12. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9, doi:10.1136/ard.2008.092767.
13. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76. (Pubitemid 351747130)
14. Rahman P, Jones A, Curtis J, et al. The Newfoundland population: a unique resource for genetic investigation of complex diseases. Hum Mol Genet 2003;12 Spec No 2:R167-72, doi:10.1093/hmg/ddg257. (Pubitemid 37259329)
15. Nall L, Gulliver W, Charmley P, Farber EM. Search for the psoriasis susceptibility gene: the Newfoundland Study. Cutis 1999;64:323-9.
16. Khraishi M, Landells I, Mugford G. The self-administered Psoriasis and Arthritis Screening Questionnaire (PASQ): a sensitive and specific tool for the diagnosis of early and established psoriatic arthritis. Psoriasis Forum 2010;16:9-16.
17. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73, doi:10.1002/art.21972. (Pubitemid 44205029)
18. Khraishi M, Jonathan M, The electronic version of the Psoriatic Arthritis Screening Questionnaire (EPASQ) is an effective tool in detecting patients with psoriatic arthritis. Presented at the American College of Rheumatology 2009 Annual Meeting; 2009 Oct 17-21; Philadelphia, PA.
19. Leung YY, Tam LS, Ho KW, et al. Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. Rheumatology 2010;49:112-5, doi:10.1093/rheumatology/kep348.
20. Husni ME, Qureshi AA, Robertson D, et al. Estimate of the prevalence of psoriatic arthritis and improvement with etanercept treatment in moderate-to-severe plaque psoriasis: PASE results from the PRISTINE Trial. Presented at the American College of Rheumatology 2010 Annual Meeting; 2010 Nov 7-11; Atlanta, GA.
21. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246-50, doi:10.1093/rheumatology/23.4.246. (Pubitemid 14015860)
22. Pattison EJ, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case control study. Ann Rheum Dis 2008;67:672-6, doi:10.1136/ard.2007.073932. (Pubitemid 351571932)
23. Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol 2002;29:757-62. (Pubitemid 34303870)
24. Scarpa R, Del Puente A, di Girolamo C, et al. Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis 1992;51:78-9, doi:10.1136/ard.51.1.78.